NeoGenomics NASDAQ: NEO executives highlighted growth in next-generation sequencing tests and expanding use of its cancer diagnostics portfolio, while outlining plans to invest further in sales and minimal residual disease testing in 2027.
Speaking at the Stephens Conference, CEO Tony Zook said the company’s clinical business, which accounts for about 93% of its business, grew 13% in the third quarter. Next-generation sequencing, or NGS, revenue rose 29%, supported by 17% volume growth, he said.
Zook described NGS as a roughly $250 million business representing about a third of NeoGenomics’ operations. Large-panel tests grew more than 25%, while average unit price rose about 11%, exceeding the company’s own expectations, he said.
Chief Operating Officer Warren Stone, who is set to become CEO, said adjusted EBITDA improved 53% year over year and the company raised its guidance. Zook also cited gross margin expansion and stronger-than-expected underlying volume.
NGS Growth and Sales Expansion
Management said its full-year expectation for NGS growth above 25% reflected prudence rather than concern about the business. Stone added that year-over-year comparisons would be tougher.
Stone attributed large-panel growth to new products, an expanded sales team and a shift in community practices toward broader panels. The company has increased its sales team to 160 people, he said.
He also pointed to the PanTracer family of solid-tumor tests. PanTracer Liquid is growing fastest by percentage among the company’s large-panel assays, although it remains on a relatively small base, Stone said.
PanTracer Tissue volume was growing well above 50%, Stone said, without providing a more precise figure. Average unit price for the test has also improved, helped by better coverage and commercial payer wins, he added.
Liquid adoption has been slower than the earlier uptake of tissue testing, partly because community physicians rely on guidelines that favor tissue as the primary standard, Stone said. Zook said NeoGenomics views liquid as part of the broader PanTracer offering and expects it to become more of a growth driver in 2028 and 2029.
Stone said an upgrade to the Neo Comprehensive Heme panel reduced turnaround time to eight to 10 days from 14 days and improved sensitivity. He expects the upgrade, introduced late in the third quarter, to support growth in 2027.
RaDaR Coverage and Outlook
NeoGenomics has begun rolling out its RaDaR ST minimal residual disease test for an immunotherapy indication. Stone said the company is actively marketing the test for three covered indications that represent about 20% of what it estimates is a $20 billion total addressable market.
Two additional indications pending coverage could increase that share to 40%, he said. Zook said the company remains confident that one coverage decision will arrive by the end of this year and the other by mid-2027. NeoGenomics is accepting orders for the pending indications but is not actively marketing them.
Stone said the company plans to continue adding sales staff ahead of new indications and products, with more details expected early in the new year.
Chief Financial Officer Abhishek Jain described mid-single-digit growth in clinical revenue as a base case for 2027 and said the company would provide full-year guidance on its fourth-quarter call. Despite tougher comparisons, he said management does not expect NGS growth momentum to slow.
Margins and Strategy
Jain said NGS growth, higher average unit prices and a sequencing-platform transition could support further gross margin expansion in 2027. Growing RaDaR volumes and PAMA were among factors he identified as potential offsets. He nevertheless said the company expects gross margins to expand next year.
Zook said the smaller non-clinical business could return to growth in 2027, though the contribution would be non-material. He said NeoGenomics intends to focus its pharma efforts on molecular testing rather than high-volume, low-value work.
As incoming CEO, Stone said he supports the company’s existing oncology strategy and intends to focus on extracting value faster, particularly in NGS and minimal residual disease testing.
About NeoGenomics (NASDAQ:NEO)
NeoGenomics is a cancer-focused diagnostics company that provides laboratory testing and related services to physicians, hospitals, pharmaceutical companies and other healthcare organizations. Its clinical testing helps support the diagnosis and treatment of cancer. The company offers a range of oncology tests, including molecular, cytogenetic, pathology and flow cytometry services. Its capabilities also include next-generation sequencing and liquid biopsy testing, which can help clinicians assess tumor characteristics and inform treatment decisions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.